ImmunityBio (IBRX) News Today $3.38 -0.07 (-2.03%) (As of 09/6/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 4 at 2:19 AM | americanbankingnews.comImmunityBio, Inc. (NASDAQ:IBRX) Sees Large Growth in Short InterestSeptember 3, 2024 | marketbeat.comShort Interest in ImmunityBio, Inc. (NASDAQ:IBRX) Grows By 5.2%ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) was the recipient of a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 49,180,000 shares, a growth of 5.2% from the July 31st total of 46,770,000 shares. Based on an average daily volume of 3,240,000 shares, the short-interest ratio is currently 15.2 days. Approximately 31.6% of the company's shares are short sold.August 30, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Up 3.7%ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.7%August 21, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Up 7.8%ImmunityBio (NASDAQ:IBRX) Stock Price Up 7.8%August 19, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Hold Rating on ImmunityBio (IBRX)August 19, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) PT Lowered to $4.75 at Piper SandlerPiper Sandler lowered their price objective on shares of ImmunityBio from $6.00 to $4.75 and set a "neutral" rating for the company in a report on Monday.August 19, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Down 6% ImmunityBio (NASDAQ:IBRX) Trading Down 6%August 19, 2024 | seekingalpha.comImmunityBio's Anktiva: Promising, But Organizational Complexity Keeps Me CautiousAugust 13, 2024 | ca.finance.yahoo.comABSI Sep 2024 6.000 callAugust 13, 2024 | msn.comCompany News for Aug 13, 2024August 13, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Down 2.7% After Earnings MissImmunityBio (NASDAQ:IBRX) Shares Down 2.7% on Disappointing EarningsAugust 12, 2024 | finance.yahoo.comImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA ApprovalAugust 9, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Stock Price Up 6.9%ImmunityBio (NASDAQ:IBRX) Stock Price Up 6.9%August 6, 2024 | finance.yahoo.comImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial CancerAugust 6, 2024 | marketbeat.comImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Vanguard Group Inc.Vanguard Group Inc. raised its holdings in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 1.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,539,590 shares of the company's stock after purchasingAugust 5, 2024 | finance.yahoo.comIBRX Aug 2024 4.000 put (IBRX240809P00004000)August 5, 2024 | finance.yahoo.comIBRX Aug 2024 6.500 call (IBRX240809C00006500)July 25, 2024 | prnewswire.comKuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law FirmJuly 23, 2024 | markets.businessinsider.comHealthcare Services Group is about to announce its earnings — here's what to expectJuly 23, 2024 | investorplace.com7 Biotech Stocks to Keep on Your Clinical RadarJuly 22, 2024 | marketbeat.comImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Blair William & Co. ILBlair William & Co. IL raised its stake in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 106.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 313,542 shares of the company's stock after buying an additional 161,530 shares durJuly 16, 2024 | marketbeat.comImmunityBio, Inc. (NASDAQ:IBRX) Short Interest Down 8.2% in JuneImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) was the target of a significant drop in short interest during the month of June. As of June 30th, there was short interest totalling 49,080,000 shares, a drop of 8.2% from the June 15th total of 53,440,000 shares. Approximately 31.8% of the shares of the company are short sold. Based on an average daily trading volume, of 6,770,000 shares, the short-interest ratio is presently 7.2 days.July 8, 2024 | seekingalpha.comImmunityBio: All Eyes On Execution Now (Rating Upgrade)June 25, 2024 | seekingalpha.comImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze PotentialJune 25, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Down 3.7% ImmunityBio (NASDAQ:IBRX) Shares Down 3.7%June 20, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Gap Up to $6.23ImmunityBio (NASDAQ:IBRX) Shares Gap Up to $6.23June 20, 2024 | investorplace.com3 Short-Squeeze Stocks Outwitting the Pessimistic PredictionsJune 18, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading 5.1% Higher ImmunityBio (NASDAQ:IBRX) Stock Price Up 5.1%June 12, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Stock Price Down 3.9%ImmunityBio (NASDAQ:IBRX) Trading Down 3.9%June 11, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Up 2.9%ImmunityBio (NASDAQ:IBRX) Trading Up 2.9%June 8, 2024 | marketbeat.com739,808 Shares in ImmunityBio, Inc. (NASDAQ:IBRX) Acquired by Rafferty Asset Management LLCRafferty Asset Management LLC bought a new position in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 739,808 shares of the coJune 7, 2024 | businesswire.comImmunityBio Announces 2024 Annual Meeting of Stockholders with Company UpdateJune 6, 2024 | seekingalpha.comImmunityBio: Anktiva's Launch Demands A ReassessmentJune 6, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Gap Down to $6.36ImmunityBio (NASDAQ:IBRX) Shares Gap Down to $6.36June 3, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Stock Price Down 3.3%ImmunityBio (NASDAQ:IBRX) Trading Down 3.3%May 31, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Up 4.4%ImmunityBio (NASDAQ:IBRX) Trading Up 4.4%May 17, 2024 | benzinga.comWhat the Options Market Tells Us About ImmunityBioMay 17, 2024 | businesswire.comConnecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday PodcastMay 16, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Down 4.2% ImmunityBio (NASDAQ:IBRX) Shares Down 4.2%May 13, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Up 8.9%ImmunityBio (NASDAQ:IBRX) Stock Price Up 8.9%May 11, 2024 | finance.yahoo.comImmunityBio First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 10, 2024 | investorplace.comIBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | investorplace.comThe 3 Best Bargain Stocks to Buy in May 2024May 8, 2024 | benzinga.comLatest News for ImmunityBio Stock (NASDAQ:IBRX)May 7, 2024 | finance.yahoo.comImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®May 7, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Gap Up to $7.81ImmunityBio (NASDAQ:IBRX) Shares Gap Up to $7.81May 6, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Down 12.6% ImmunityBio (NASDAQ:IBRX) Shares Down 12.6%May 6, 2024 | investorplace.comEven Worse than Gamestop? 3 Meme Stocks That Are Screaming SellsMay 3, 2024 | msn.comSerum Institute of India Inks Large-Scale Supply Deal For BCG Use In ImmunityBio's Bladder Cancer Combo TherapyMay 2, 2024 | businesswire.comImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address NASDAQ to crash 50%? (Ad)During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy... Click here to learn more >>> IBRX Media Mentions By Week IBRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IBRX News Sentiment▼0.590.55▲Average Medical News Sentiment IBRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IBRX Articles This Week▼32▲IBRX Articles Average Week Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VCYT News HRMY News BCRX News SANA News FLGT News ITOS News ALEC News SAGE News EBS News TSHA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IBRX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
